List view / Grid view
Aduhelm™ (aducanumab-avwa) is the first new treatment approved for Alzheimer’s…
Aduhelm™ (aducanumab-avwa) is the first new treatment approved for Alzheimer’s since 2003 and the first therapy to target the fundamental pathophysiology of the disease – amyloid plaques.
Aducanumab, an Alzheimer's disease treatment, will be submitted as part…
Aducanumab, an Alzheimer's disease treatment, will be submitted as part of a Biologics License Application after meeting clinical trial primary endpoints.
Commits $1.5 billion to R&D in China over the next…
6 December 2011 | By
Commits $1.5 billion to R&D in China over the next 5 years...
Merck & Co., Inc., and Simcere announced the signing of…
21 July 2011 | By Merck
Merck & Co., Inc., and Simcere announced the signing of a framework agreement to establish a joint venture...
